These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 11271207

  • 1. Renal complications and development of hypertension in the European study of FK 506 and cyclosporin in primary liver transplant recipients.
    Devlin J, Williams R, Neuhaus P, McMaster P, Calne R, Pichlmayr R, Otto G, Bismuth H, Groth C.
    Transpl Int; 1994; 7 Suppl 1():S22-6. PubMed ID: 11271207
    [Abstract] [Full Text] [Related]

  • 2. Glucose metabolism in liver transplant recipients treated with FK 506 or cyclosporin in the European multicentre study.
    Ericzon B, Groth C, Bismuth H, Calne R, McMaster P, Neuhaus P, Otto G, Pichlmayr R, Williams R.
    Transpl Int; 1994; 7 Suppl 1():S11-4. PubMed ID: 11271178
    [Abstract] [Full Text] [Related]

  • 3. Neurological complications in the European multicentre study of FK 506 and cyclosporin in primary liver transplantation.
    Neuhaus P, McMaster P, Calne R, Pichlmayr R, Otto G, Williams R, Bismuth H, Groth C.
    Transpl Int; 1994; 7 Suppl 1():S27-31. PubMed ID: 11271222
    [Abstract] [Full Text] [Related]

  • 4. Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation.
    Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH.
    Mayo Clin Proc; 1994 Feb; 69(2):105-11. PubMed ID: 7508536
    [Abstract] [Full Text] [Related]

  • 5. Comparison of short and long-term renal function in liver transplant patients receiving cyclosporin or FK 506.
    Mor E, Patel T, Glabman S, Sheiner P, Emre S, Guy S, Schwartz M, Miller C.
    Transpl Int; 1994 Feb; 7 Suppl 1():S77-80. PubMed ID: 11271340
    [Abstract] [Full Text] [Related]

  • 6. Nephrotoxicity after orthotopic liver transplantation in cyclosporin A and FK 506-treated patients.
    Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P.
    Transpl Int; 1994 Feb; 7 Suppl 1():S52-7. PubMed ID: 11271297
    [Abstract] [Full Text] [Related]

  • 7. Pronounced renal vasoconstriction and systemic hypertension in renal transplant patients treated with cyclosporin A versus FK 506.
    Radermacher J, Meiners M, Bramlage C, Kliem V, Behrend M, Schlitt HJ, Pichlmayr R, Koch KM, Brunkhorst R.
    Transpl Int; 1998 Feb; 11(1):3-10. PubMed ID: 9503547
    [Abstract] [Full Text] [Related]

  • 8. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial.
    Jonas S, Kling N, Bechstein WO, Blumhardt G, Lohmann R, Lobeck H, Neuhaus P.
    Clin Transplant; 1995 Oct; 9(5):406-14. PubMed ID: 8541635
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Immunosuppression switch in pediatric heart transplant recipients: cyclosporine to FK 506.
    Swenson JM, Fricker FJ, Armitage JM.
    J Am Coll Cardiol; 1995 Apr; 25(5):1183-8. PubMed ID: 7534779
    [Abstract] [Full Text] [Related]

  • 11. Patient and graft survival in the European Multicentre Liver Study--FK 506 vs cyclosporin A.
    McMaster P.
    Transpl Int; 1994 Apr; 7 Suppl 1():S32-6. PubMed ID: 11271239
    [Abstract] [Full Text] [Related]

  • 12. FK 506 primary immunosuppression following emergency liver transplantation for fulminant hepatic failure. European FK 506 Study Liver Group.
    Devlin J, Wong P, Williams R, Neuhaus P, McMaster P, Calne R, Pichlmayr R, Otto G, Bismuth H, Groth C.
    Transpl Int; 1994 Apr; 7 Suppl 1():S64-9. PubMed ID: 11271328
    [Abstract] [Full Text] [Related]

  • 13. Impact of Sandimmune, Neoral, and Prograf on rejection incidence and renal function in primary liver transplant recipients.
    Van Buren D, Payne J, Geevarghese S, MacDonell R, Chapman W, Wright JK, Helderman JH, Richie R, Pinson CW.
    Transplant Proc; 1998 Aug; 30(5):1830-2. PubMed ID: 9723299
    [Abstract] [Full Text] [Related]

  • 14. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil.
    Herrero JI, Quiroga J, Sangro B, Girala M, Gómez-Manero N, Pardo F, Alvárez-Cienfuegos J, Prieto J.
    Liver Transpl Surg; 1999 Sep; 5(5):414-20. PubMed ID: 10477843
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
    Shenoy S, Hardinger KL, Crippin J, Korenblat K, Lisker-Melman M, Lowell JA, Chapman W.
    Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
    [Abstract] [Full Text] [Related]

  • 17. FK 506 versus cyclosporin in the prevention of renal allograft rejection--European pilot study: six-week results.
    Schleibner S, Krauss M, Wagner K, Erhard J, Christiaans M, van Hooff J, Buist L, Mayer D.
    Transpl Int; 1995 Feb; 8(2):86-90. PubMed ID: 7539270
    [Abstract] [Full Text] [Related]

  • 18. Renal function in primary liver transplant recipients receiving neoral (cyclosporine) versus prograf (tacrolimus).
    Van Buren D, Payne J, Geevarghese S, MacDonell R, Chapman W, Wright JK, Helderman JH, Richie R, Pinson CW.
    Transplant Proc; 1998 Jun; 30(4):1401-2. PubMed ID: 9636566
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Oral health in renal transplant recipients administered cyclosporin A or tacrolimus.
    Spolidorio LC, Spolidorio DM, Massucato EM, Neppelenbroek KH, Campanha NH, Sanches MH.
    Oral Dis; 2006 May; 12(3):309-14. PubMed ID: 16700742
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.